Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 237722
                    [Title] => Results of landmark heart study bared
                    [Summary] => More than 2,000 heart specialists and other practicing physicians gathered at the Le Pavillion in Manila last Jan. 22 to listen to the presentation of the results and clinical implications of a landmark study that researchers hope will change the medical landscape in the management of heart diseases.


Results of VALIANT (Valsartan in Acute Myocardial Infarction Trial) was presented to doctors from all over the country by Prof. Inder Anand, chief of the Cardiology Section of the Veterans Affair Medical Center in Minneapolis, USA. 


                    [DatePublished] => 2004-02-05 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [1] => Array
                (
                    [ArticleID] => 236012
                    [Title] => Landmark trial shows benefits of ‘valsartan’
                    [Summary] => Internationally respected medical authorities reported at the American Heart Association meeting held recently in Orlando, Florida that valsartan, a drug for high blood pressure belonging to the angiotensin II receptor blocker (ARB) family, is as effective as the ACE-inhibitor captopril in reducing the risk of death and other non-fatal cardiovascular events (CV) among high-risk patients, as results of the VALIANT study show.


                    [DatePublished] => 2004-01-22 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [2] => Array
                (
                    [ArticleID] => 228628
                    [Title] => Landmark study presented in US gab
                    [Summary] => More than 25,000 heart specialists and researchers gathered at the Orange County Convention Center in Orlando, Florida recently for the 76th annual scientific sessions of the American Heart Association (AHA) to discuss new developments in the management of cardiovascular diseases. 


Researchers said a new clinical study provides evidence that treatment of heart attack patients with the angiotensin receptor blocker valsartan is as effective as the proven dose of the angiotensin-converting enzyme (ACE) inhibitor captopril. 


                    [DatePublished] => 2003-11-20 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

ACUTE MYOCARDIAL INFARCTION TRIAL

Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 237722
                    [Title] => Results of landmark heart study bared
                    [Summary] => More than 2,000 heart specialists and other practicing physicians gathered at the Le Pavillion in Manila last Jan. 22 to listen to the presentation of the results and clinical implications of a landmark study that researchers hope will change the medical landscape in the management of heart diseases.


Results of VALIANT (Valsartan in Acute Myocardial Infarction Trial) was presented to doctors from all over the country by Prof. Inder Anand, chief of the Cardiology Section of the Veterans Affair Medical Center in Minneapolis, USA. 


                    [DatePublished] => 2004-02-05 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [1] => Array
                (
                    [ArticleID] => 236012
                    [Title] => Landmark trial shows benefits of ‘valsartan’
                    [Summary] => Internationally respected medical authorities reported at the American Heart Association meeting held recently in Orlando, Florida that valsartan, a drug for high blood pressure belonging to the angiotensin II receptor blocker (ARB) family, is as effective as the ACE-inhibitor captopril in reducing the risk of death and other non-fatal cardiovascular events (CV) among high-risk patients, as results of the VALIANT study show.


                    [DatePublished] => 2004-01-22 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [2] => Array
                (
                    [ArticleID] => 228628
                    [Title] => Landmark study presented in US gab
                    [Summary] => More than 25,000 heart specialists and researchers gathered at the Orange County Convention Center in Orlando, Florida recently for the 76th annual scientific sessions of the American Heart Association (AHA) to discuss new developments in the management of cardiovascular diseases. 


Researchers said a new clinical study provides evidence that treatment of heart attack patients with the angiotensin receptor blocker valsartan is as effective as the proven dose of the angiotensin-converting enzyme (ACE) inhibitor captopril. 


                    [DatePublished] => 2003-11-20 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

abtest

Results of landmark heart study bared

February 5, 2004 - 12:00am

More than 2,000 heart specialists and other practicing physicians gathered at the Le Pavillion in Manila last Jan. 22 to listen to the presentation of the results and clinical implications of a landmark study that...

Science and Environment

Landmark trial shows benefits of ‘valsartan’

January 22, 2004 - 12:00am

Internationally respected medical authorities reported at the American Heart Association meeting held recently in Orlando, Florida that valsartan, a drug for high blood pressure belonging to the angiotensin II receptor...

Science and Environment

Landmark study presented in US gab

November 20, 2003 - 12:00am

More than 25,000 heart specialists and researchers gathered at the Orange County Convention Center in Orlando, Florida recently for the 76th annual scientific sessions of the American Heart Association (AHA) to discuss...

Science and Environment